[ad_1]
At the edge “Significant discovery” in effort vaccine development against coronavirus announced today, Tuesday, that the German biotech company CureVac, in which the German State has been participating for a few months.
According to the Chairman of the Board. of the company, Franz – Werner Haas, who was a guest on today’s Steingard podcast, early studies show “dynamic Y very effective immune response “ and now the decisive phase 2b / 3 has begun, with 25,000 participants.
Haas estimated that his company would receive a permit from the US authorities no later than spring, noting that it was about three months behind the competition.
Earlier, European Health Commissioner Stella Kyriakidou announced that The European Union concludes negotiations with the American Pfizer and the German BioNTech and will sign a contract “in the next few days” for the purchase of 300 million doses of its vaccine against Covid-19.
“I believe that the agreement will be approved on Wednesday by the College of Commissioners”, the procedures will continue three or four days“To ensure the green light of the Member States and ‘then we will sign'”, explained the European Commissioner.
The European Commission had arrived preliminary agreement In early September, the two companies pre-ordered 200 million doses of their vaccine, with the option to supply an additional 100 million doses.
